| |
|
|
|
Center for Bio-Medical Communication, Inc., The Westin Bonaventure Hotel and Suites, 404 South Figueroa St., Los Angeles, California
5/22/06 6:15 PM - 8:30 PM
WHO SHOULD ATTEND
This program has been developed to educate physicians and other healthcare
professionals involved in the care of patients with chronic hepatitis C.
NEEDS ASSESSMENT
Despite considerable strides made in preventing and managing hepatitis C infection
over the past 2 decades, an estimated 4 million Americans are infected with
hepatitis C virus (HCV). With the knowledge gained from decades of experience,
an improved understanding of the degrees of response by treatment group has
been established showing a need for enhanced treatment and diagnostic options
in traditionally highly refractive groups, such as patients coinfected with HCV and
HIV or those with genotype 1.
As treatment strategies are developed and improved, physicians across the continuum
of care, from diagnosis and referral to management of special patient groups and
non-responding patients, have a need to understand the latest advances and findings
regarding treatment of this often-devastating infection. New agents with a different
mechanism of action and potent antiviral activity promise to provide substantial
improvements over current therapies. The elements offered in this symposium cover
data from established studies and will provide new insight from ongoing clinical trials
to help hepatitis specialists better manage patients with HCV infections.
|
|
|
|
|
|
|
|
Organized by:
|
|
Center for Bio-Medical Communications, Inc. |
|
|
Invited Speakers:
|
|
Eugene R. Schiff, MD, MACP, FRCP, MACG
Kenneth E. Sherman, MD, PhD
Robert S. Brown, Jr., MD, MPH
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
On line at www.cbcbiomed.com
|
|
|
E-mail:
|
|
dvalencia@cbcbiomed.com
|
|
|
|
|
|
|
|
|